DBV Technologies | DBVT - Operating Expenses


DBV Technologies reported $47.9M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.12M 2.55M Jun/2026
Alnylam Pharmaceuticals USD 1.06B 160.97M Jun/2026
Amarin USD 51.48M 113K Dec/2025
BioCryst Pharmaceuticals USD 119.78M 673.63M Jun/2026
BioMarin Pharmaceutical USD 6.32B 5.69B Jun/2026
DBV Technologies USD 47.9M 2.2M Mar/2026
Galectin Therapeutics USD 11.29M 1.64M Jun/2024
Halozyme Therapeutics USD 193.34M 1.15M Jun/2026
Incyte USD 973.64M 4.65B Jun/2026
Insmed USD 526.79M 20.55M Jun/2026
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
Neurocrine Biosciences USD 739.1M 139.2M Jun/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Sarepta Therapeutics USD 387.96M 15.59M Jun/2026
Ultragenyx Pharmaceutical USD 289M 16M Jun/2026
United Therapeutics USD 6.4B 499.2M Jun/2026